[Refractory respiratory tract infections. 7. Trends in the development of new chemotherapeutic agents for respiratory tract infections. c. Combinations of beta-lactam antibiotics and beta-lactamases inhibitors].
D000658:Amoxicillin / Q000627:therapeutic use*; D000667:Ampicillin / Q000627:therapeutic use*; D002438:Cefoperazone / Q000627:therapeutic use*; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000627:therapeutic use*; D004338:Drug Combinations; D006801:Humans; D010397:Penicillanic Acid / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D013407:Sulbactam; D013982:Ticarcillin / Q000627:therapeutic use*; D065093:beta-Lactamase Inhibitors
D002969:Clavulanic Acids; D004338:Drug Combinations; D010406:Penicillins; D065093:beta-Lactamase Inhibitors; D019818:Clavulanic Acid; D000667:Ampicillin; D002438:Cefoperazone; D000658:Amoxicillin; D010397:Penicillanic Acid; D013982:Ticarcillin; D013407:Sulbactam